PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/495, 9/20 — A2

(11) International Publication Number: WO 00/13687

(43) International Publication Date: 16 March 2000 (16.03.00)

(21) International Application Number: PCT/US99/20968

(22) International Filing Date: 9 September 1999 (09.09.99)

(30) Priority Data:

60/099,804	10 September 1998 (10.09.98)	US
09/321,522	27 May 1999 (27.05.99)	US

(71) Applicant *(for all designated States except US)*: CV THERAPEUTICS, INC. [US/US]; 3172 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: WOLFF, Andrew, A. [US/US]; 1140 Lawton Street, San Francisco, CA 94122 (US).

(74) Agent: HUGHES, A., Blair; McDonnell, Boehnen, Hulbert & Berghoff, Suite 3200, 300 S. Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: SUSTAINED RELEASE RANOLAZINE FORMULATIONS

(57) Abstract

A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.